BTIS
MYGN icon

BB&T Investment Services’s Myriad Genetics MYGN Stock Holding History

BB&T Investment Services’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,422
Closed -$90K – 1303
2017
Q2 		$90K Buy
3,422
+464
+16% +$9.85K 0.02% 348
2017
Q1 		$57K Buy
2,958
+31
+1% +$549 0.02% 347
2016
Q4 		$49K Buy
+2,927
New +$53K 0.04% 301

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BB&T Investment Services's MYGN Position: Q3 2017 in Review

BB&T Investment Services sold out of Myriad Genetics (MYGN) in Q3 2017, closing a stake of 3,422 shares — an estimated $90K sold.

BB&T Investment Services first reported a position in MYGN in Q4 2016 and held it in 3 quarters. The position peaked at $90K in Q2 2017. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

  • BB&T Investment Services reported no remaining Myriad Genetics position as of Q3 2017 after selling out during the quarter.
  • BB&T Investment Services sold 3,422 Myriad Genetics shares in Q3 2017, an estimated $90K.
  • BB&T Investment Services first reported a position in Myriad Genetics in Q4 2016 and held it in 3 quarters.
  • BB&T Investment Services's Myriad Genetics position peaked at $90K in Q2 2017.
  • 220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on BB&T Investment Services's 13F filing for Q3 2017, filed 13 Nov 2017.